Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer

xlomafota13 shared this article with you from Inoreader Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer Via Association française pour l'étude du cancer Bull Cancer. 2021 Sep 28:S0007-4551(21)00301-5. doi: 10.1016/j.bulcan.2021.05.009. Online ahead of print. NO ABSTRACT PMID:34598787 | DOI:10.1016/j.bulcan.2021.05.009 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.